id: NEW:baclofen_pharmacotherapy_aud_to_NEW:alcohol_craving
name: Baclofen Pharmacotherapy for Alcohol Use Disorder â†’ Alcohol Craving Intensity
from_node:
  node_id: NEW:baclofen_pharmacotherapy_aud
  node_name: Baclofen Pharmacotherapy for Alcohol Use Disorder
to_node:
  node_id: NEW:alcohol_craving
  node_name: Alcohol Craving Intensity
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Baclofen administered at doses up to 50-60 mg/day activates GABA-B receptors in the central
  nervous system'
- 'Step 2: GABA-B activation reduces neuronal excitability in circuits associated with craving and compulsive
  alcohol seeking'
- 'Step 3: Modulation of stress-related pathways and anxiety circuits that trigger craving responses'
- 'Step 4: Decreased subjective experience of craving for alcohol'
- 'Step 5: Reduced craving supports sustained engagement with treatment and recovery'
evidence:
  quality_rating: A
  n_studies: 14
  primary_citation: 'Kazumasa Kotake et al. 2025. "Optimal Dose of Baclofen for the Treatment of Alcohol
    Use Disorder: A Systematic Review and Dose-Response Meta-analysis.." https://doi.org/10.1007/s40263-025-01188-2'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 14 randomized controlled trials
  - Studies identified through Cochrane, EMBASE, MEDLINE via PubMed, PsycINFO databases
  - ClinicalTrials.gov and International Clinical Trials Registry Platform searches conducted April 2024
  doi: 10.1007/s40263-025-01188-2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Baclofen at optimal doses (50-60 mg/day) reduces alcohol craving in patients with AUD, addressing
  a core neurobiological feature of addiction that drives relapse and continued use.
quantitative_effects:
  sample_size: 1344
moderators:
- name: baclofen_dose
  direction: strengthens
  strength: strong
  description: Increasing doses up to 50-60 mg/day associated with greater craving reduction
structural_competency:
  equity_implications: Craving is a neurobiological phenomenon influenced by environmental triggers including
    stress, social context, and alcohol availability. Medication-assisted treatment that addresses craving
    represents a structural intervention that reduces reliance on individual willpower alone. Access to
    this treatment modality depends on healthcare infrastructure, prescriber knowledge, and insurance
    coverage - all structural factors that vary by geography and socioeconomic status.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.900471'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
